This shows you the differences between two versions of the page.
Both sides previous revision Previous revision Next revision | Previous revision Next revision Both sides next revision | ||
home:publications [16.11.2019 19:14] Teemu Kuulasmaa [2018] |
home:publications [19.11.2019 10:46] Juha Kekäläinen |
||
---|---|---|---|
Line 5: | Line 5: | ||
### 2019 | ### 2019 | ||
+ | |||
+ | Karttunen, J.; Heiskanen, M.; Lipponen, A.; Poulsen, D.; Pitkänen, A. **Extracellular Vesicles as Diagnostics and Therapeutics for Structural Epilepsies**, | ||
Failli M, Paananen J, Fortino V. **Prioritizing target-disease associations with novel safety and efficacy scoring methods**, //Sci Rep// 2019, https:// | Failli M, Paananen J, Fortino V. **Prioritizing target-disease associations with novel safety and efficacy scoring methods**, //Sci Rep// 2019, https:// | ||
Line 10: | Line 12: | ||
Timonen O, Särkkä M, Fülöp T, Mattsson A, Kekäläinen J, Paananen J, **Varanto: variant enrichment analysis and annotation**, | Timonen O, Särkkä M, Fülöp T, Mattsson A, Kekäläinen J, Paananen J, **Varanto: variant enrichment analysis and annotation**, | ||
- | Lipponen A, Natunen T, Hujo M, Ciszek R, Hämäläinen E, Tohka J, Hiltunen M, Paananen J, Poulsen D, Kansanen E, Ndode-Ekane | + | Lipponen A, Natunen T, Hujo M, Ciszek R, Hämäläinen E, Tohka J, Hiltunen M, Paananen J, Poulsen D, Kansanen E, Ndode-Ekane |
- | Pölönen P, Mehtonen J, Lin J, Liuksiala T, Häyrynen S, Teppo S, Mäkinen A, Kumar A, Malani D, Pohjolainen V, Porkka K, Heckman | + | Pölönen P, Mehtonen J, Lin J, Liuksiala T, Häyrynen S, Teppo S, Mäkinen A, Kumar A, Malani D, Pohjolainen V, Porkka K, Heckman |
Mehtonen J, Pölönen P, Häyrynen S, Lin J, Liuksiala T, Granberg K, Lohi O, Hautamäki V, Nykter M, Heinäniemi M. **Data-driven characterization of molecular phenotypes across heterogenous sample collections**, | Mehtonen J, Pölönen P, Häyrynen S, Lin J, Liuksiala T, Granberg K, Lohi O, Hautamäki V, Nykter M, Heinäniemi M. **Data-driven characterization of molecular phenotypes across heterogenous sample collections**, | ||
Line 41: | Line 43: | ||
### 2017 or earlier | ### 2017 or earlier | ||
- | - to be listed here later... | + | Paananen, J. **Bioinformatics in the Identification of Novel Targets and Pathways in Neurodegenerative Diseases**, Curr Genet Med Rep (2017) 5:15–21, https://doi.org/10.1007/ |